Quarterly report pursuant to Section 13 or 15(d)

Goodwill and Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details)

v3.20.4
Goodwill and Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Finite-lived Intangible Asset, Useful Life (Years) 5 years  
Finite-lived Intangible Assets, Gross $ 39,288 $ 39,288
Finite-lived Intangible Assets, Accumulated Amortization (24,554) (23,439)
Finite-lived Intangible Assets, Net Carrying Value $ 14,734 15,849
CLIA Lab [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 2 years 3 months 19 days  
Finite-lived Intangible Assets, Gross $ 609 609
Asuragen Acquisition [Member] | Thyroid [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 9 years  
Finite-lived Intangible Assets, Gross $ 8,519 8,519
RedPath Acquisition [Member] | Pancreas Test [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 7 years  
Finite-lived Intangible Assets, Gross $ 16,141 16,141
RedPath Acquisition [Member] | Barrett's Test [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 9 years  
Finite-lived Intangible Assets, Gross $ 6,719 6,719
BioPharma Acquisition [Member] | Trademarks [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 10 years  
Finite-lived Intangible Assets, Gross $ 1,600 1,600
BioPharma Acquisition [Member] | Customer Relationships [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 8 years  
Finite-lived Intangible Assets, Gross $ 5,700 $ 5,700